세계의 식물성 의약품 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Botanical Drug was estimated to be worth US$ 36921 million in 2024 and is forecast to a readjusted size of US$ 49076 million by 2031 with a CAGR of 4.3% during the forecast period 2025-2031.

Botanical drugs are therapeutic products derived from natural plants or their active ingredients, developed through modern pharmaceutical science, manufacturing processes, and clinical research. Compared with synthetic chemical drugs, botanical drugs feature natural origins, complex compositions, and multi-target mechanisms, representing a fusion of traditional medicine theories and modern scientific advancements. They include both traditional herbal preparations and innovative botanical-based drugs that meet international regulatory standards, with applications spanning chronic disease management, anti-infective therapies, cardiovascular care, oncology, and immunomodulation. Their development and production strictly follow GMP guidelines and advanced quality control systems to ensure consistency, efficacy, and safety. In recent years, driven by consumer preference for natural health solutions and the rise of precision medicine, botanical drugs have emerged as a key segment of the global pharmaceutical market, attracting strong policy support and investor interest.

The global botanical drug industry is experiencing growth fueled by both regulatory support and market demand. Regulatory agencies worldwide are refining herbal medicine registration standards and pharmacopoeia specifications, accelerating the globalization of botanical drugs. Rising health awareness and consumer preference for natural therapies create vast market potential. With aging populations and increasing prevalence of chronic diseases, botanical drugs are playing a vital role in cardiovascular health, diabetes care, oncology recovery, and more. Capital investment and active participation by multinational pharmaceutical companies are driving innovation, while advances in standardized extraction, active compound analysis, and intelligent manufacturing are accelerating commercialization and international market expansion.

Despite promising prospects, the botanical drug sector faces significant hurdles, including complex clinical validation, lengthy regulatory approval processes, and inconsistent quality standards. The inherent complexity of plant-based formulations requires substantial investment in R&D and quality control, particularly to meet stringent FDA and EMA approval criteria. Intellectual property protection remains a challenge, with counterfeit products impacting brand reputation and market order. Raw material costs are sensitive to environmental and climatic factors, leading to supply chain instability. Stricter regulations and trade barriers further compel companies to invest heavily in compliance, R&D, and market expansion, raising barriers to entry.

Global consumers' growing preference for natural, sustainable, and personalized healthcare solutions is energizing the botanical drug market. Pharmaceutical companies are rapidly developing standardized botanical formulations while extending their reach into functional foods and health management products. Botanical drugs are gaining traction in hospitals, pharmacies, and online sales channels, particularly for chronic disease care, oncology support, and wellness therapies. Cross-border e-commerce and global marketing strategies are helping culturally distinctive botanical brands expand internationally. Additionally, digital health platforms, product traceability systems, and personalized medicine are shaping the transition of botanical drugs from traditional remedies to modern precision healthcare solutions.

The backbone of botanical drug manufacturing lies in diverse medicinal plant resources, with production involving cultivation, harvesting, processing, and primary extraction. Advanced cultivation methods and ecological harvesting practices have become essential for securing a stable, high-quality supply chain. Growing emphasis on sustainable farming and GAP-certified plantations has improved traceability and consistency of herbal materials. As wild harvesting faces constraints due to climate change and conservation policies, large-scale commercial cultivation has emerged in regions such as China, India, and Southeast Asia, forming global supply hubs. Progress in extraction and purification technologies is enabling standardized raw materials, supporting high-end drug development and regulatory compliance. A globalized sourcing network and modern logistics infrastructure now allow companies to better manage seasonal fluctuations and dynamic market demands.

This report aims to provide a comprehensive presentation of the global market for Botanical Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Botanical Drug by region & country, by Type, and by Application.

The Botanical Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Botanical Drug.

Market Segmentation

By Company

• Buchang Pharmaceuticals
• China TCM
• Tsumura
• Schwabe
• Tong Ren Tang
• Jumpcan Pharmaceutical
• Guangzhou Baiyunshan Pharmaceutical
• Yunnan Baiyao
• Tasly Holding Group
• Bionorica Se
• Huarun 999
• Taiji
• Weleda
• Kwangdong
• GW Pharmaceuticals

Segment by Type

• Prescription Drug
• OTC

Segment by Application

• Cardiovascular
• Tumor
• Respiratory System
• Other

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Botanical Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Botanical Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Botanical Drug in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Botanical Drug Product Introduction
• 1.2 Global Botanical Drug Market Size Forecast (2020-2031)
• 1.3 Botanical Drug Market Trends & Drivers
  • 1.3.1 Botanical Drug Industry Trends
  • 1.3.2 Botanical Drug Market Drivers & Opportunity
  • 1.3.3 Botanical Drug Market Challenges
  • 1.3.4 Botanical Drug Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Botanical Drug Players Revenue Ranking (2024)
• 2.2 Global Botanical Drug Revenue by Company (2020-2025)
• 2.3 Key Companies Botanical Drug Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Botanical Drug Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Botanical Drug
• 2.6 Botanical Drug Market Competitive Analysis
  • 2.6.1 Botanical Drug Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Botanical Drug Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Botanical Drug as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Prescription Drug
  • 3.1.2 OTC
• 3.2 Global Botanical Drug Sales Value by Type
  • 3.2.1 Global Botanical Drug Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Botanical Drug Sales Value, by Type (2020-2031)
  • 3.2.3 Global Botanical Drug Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Cardiovascular
  • 4.1.2 Tumor
  • 4.1.3 Respiratory System
  • 4.1.4 Other
• 4.2 Global Botanical Drug Sales Value by Application
  • 4.2.1 Global Botanical Drug Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Botanical Drug Sales Value, by Application (2020-2031)
  • 4.2.3 Global Botanical Drug Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Botanical Drug Sales Value by Region
  • 5.1.1 Global Botanical Drug Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Botanical Drug Sales Value by Region (2020-2025)
  • 5.1.3 Global Botanical Drug Sales Value by Region (2026-2031)
  • 5.1.4 Global Botanical Drug Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Botanical Drug Sales Value, 2020-2031
  • 5.2.2 North America Botanical Drug Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Botanical Drug Sales Value, 2020-2031
  • 5.3.2 Europe Botanical Drug Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Botanical Drug Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Botanical Drug Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Botanical Drug Sales Value, 2020-2031
  • 5.5.2 South America Botanical Drug Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Botanical Drug Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Botanical Drug Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Botanical Drug Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Botanical Drug Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Botanical Drug Sales Value, 2020-2031
  • 6.3.2 United States Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Botanical Drug Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Botanical Drug Sales Value, 2020-2031
  • 6.4.2 Europe Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Botanical Drug Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Botanical Drug Sales Value, 2020-2031
  • 6.5.2 China Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Botanical Drug Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Botanical Drug Sales Value, 2020-2031
  • 6.6.2 Japan Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Botanical Drug Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Botanical Drug Sales Value, 2020-2031
  • 6.7.2 South Korea Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Botanical Drug Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Botanical Drug Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Botanical Drug Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Botanical Drug Sales Value, 2020-2031
  • 6.9.2 India Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Botanical Drug Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Buchang Pharmaceuticals
  • 7.1.1 Buchang Pharmaceuticals Profile
  • 7.1.2 Buchang Pharmaceuticals Main Business
  • 7.1.3 Buchang Pharmaceuticals Botanical Drug Products, Services and Solutions
  • 7.1.4 Buchang Pharmaceuticals Botanical Drug Revenue (US$ Million) & (2020-2025)
  • 7.1.5 Buchang Pharmaceuticals Recent Developments
• 7.2 China TCM
  • 7.2.1 China TCM Profile
  • 7.2.2 China TCM Main Business
  • 7.2.3 China TCM Botanical Drug Products, Services and Solutions
  • 7.2.4 China TCM Botanical Drug Revenue (US$ Million) & (2020-2025)
  • 7.2.5 China TCM Recent Developments
• 7.3 Tsumura
  • 7.3.1 Tsumura Profile
  • 7.3.2 Tsumura Main Business
  • 7.3.3 Tsumura Botanical Drug Products, Services and Solutions
  • 7.3.4 Tsumura Botanical Drug Revenue (US$ Million) & (2020-2025)
  • 7.3.5 Tsumura Recent Developments
• 7.4 Schwabe
  • 7.4.1 Schwabe Profile
  • 7.4.2 Schwabe Main Business
  • 7.4.3 Schwabe Botanical Drug Products, Services and Solutions
  • 7.4.4 Schwabe Botanical Drug Revenue (US$ Million) & (2020-2025)
  • 7.4.5 Schwabe Recent Developments
• 7.5 Tong Ren Tang
  • 7.5.1 Tong Ren Tang Profile
  • 7.5.2 Tong Ren Tang Main Business
  • 7.5.3 Tong Ren Tang Botanical Drug Products, Services and Solutions
  • 7.5.4 Tong Ren Tang Botanical Drug Revenue (US$ Million) & (2020-2025)
  • 7.5.5 Tong Ren Tang Recent Developments
• 7.6 Jumpcan Pharmaceutical
  • 7.6.1 Jumpcan Pharmaceutical Profile
  • 7.6.2 Jumpcan Pharmaceutical Main Business
  • 7.6.3 Jumpcan Pharmaceutical Botanical Drug Products, Services and Solutions
  • 7.6.4 Jumpcan Pharmaceutical Botanical Drug Revenue (US$ Million) & (2020-2025)
  • 7.6.5 Jumpcan Pharmaceutical Recent Developments
• 7.7 Guangzhou Baiyunshan Pharmaceutical
  • 7.7.1 Guangzhou Baiyunshan Pharmaceutical Profile
  • 7.7.2 Guangzhou Baiyunshan Pharmaceutical Main Business
  • 7.7.3 Guangzhou Baiyunshan Pharmaceutical Botanical Drug Products, Services and Solutions
  • 7.7.4 Guangzhou Baiyunshan Pharmaceutical Botanical Drug Revenue (US$ Million) & (2020-2025)
  • 7.7.5 Guangzhou Baiyunshan Pharmaceutical Recent Developments
• 7.8 Yunnan Baiyao
  • 7.8.1 Yunnan Baiyao Profile
  • 7.8.2 Yunnan Baiyao Main Business
  • 7.8.3 Yunnan Baiyao Botanical Drug Products, Services and Solutions
  • 7.8.4 Yunnan Baiyao Botanical Drug Revenue (US$ Million) & (2020-2025)
  • 7.8.5 Yunnan Baiyao Recent Developments
• 7.9 Tasly Holding Group
  • 7.9.1 Tasly Holding Group Profile
  • 7.9.2 Tasly Holding Group Main Business
  • 7.9.3 Tasly Holding Group Botanical Drug Products, Services and Solutions
  • 7.9.4 Tasly Holding Group Botanical Drug Revenue (US$ Million) & (2020-2025)
  • 7.9.5 Tasly Holding Group Recent Developments
• 7.10 Bionorica Se
  • 7.10.1 Bionorica Se Profile
  • 7.10.2 Bionorica Se Main Business
  • 7.10.3 Bionorica Se Botanical Drug Products, Services and Solutions
  • 7.10.4 Bionorica Se Botanical Drug Revenue (US$ Million) & (2020-2025)
  • 7.10.5 Bionorica Se Recent Developments
• 7.11 Huarun 999
  • 7.11.1 Huarun 999 Profile
  • 7.11.2 Huarun 999 Main Business
  • 7.11.3 Huarun 999 Botanical Drug Products, Services and Solutions
  • 7.11.4 Huarun 999 Botanical Drug Revenue (US$ Million) & (2020-2025)
  • 7.11.5 Huarun 999 Recent Developments
• 7.12 Taiji
  • 7.12.1 Taiji Profile
  • 7.12.2 Taiji Main Business
  • 7.12.3 Taiji Botanical Drug Products, Services and Solutions
  • 7.12.4 Taiji Botanical Drug Revenue (US$ Million) & (2020-2025)
  • 7.12.5 Taiji Recent Developments
• 7.13 Weleda
  • 7.13.1 Weleda Profile
  • 7.13.2 Weleda Main Business
  • 7.13.3 Weleda Botanical Drug Products, Services and Solutions
  • 7.13.4 Weleda Botanical Drug Revenue (US$ Million) & (2020-2025)
  • 7.13.5 Weleda Recent Developments
• 7.14 Kwangdong
  • 7.14.1 Kwangdong Profile
  • 7.14.2 Kwangdong Main Business
  • 7.14.3 Kwangdong Botanical Drug Products, Services and Solutions
  • 7.14.4 Kwangdong Botanical Drug Revenue (US$ Million) & (2020-2025)
  • 7.14.5 Kwangdong Recent Developments
• 7.15 GW Pharmaceuticals
  • 7.15.1 GW Pharmaceuticals Profile
  • 7.15.2 GW Pharmaceuticals Main Business
  • 7.15.3 GW Pharmaceuticals Botanical Drug Products, Services and Solutions
  • 7.15.4 GW Pharmaceuticals Botanical Drug Revenue (US$ Million) & (2020-2025)
  • 7.15.5 GW Pharmaceuticals Recent Developments

8 Industry Chain Analysis

• 8.1 Botanical Drug Industrial Chain
• 8.2 Botanical Drug Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Botanical Drug Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Botanical Drug Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer